Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
biopharma-reporter
5h
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
biopharma-reporter
6h
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
biopharma-reporter
8h
We’ve upgraded BioPharmaReporter to give you more of what you love
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Backs ceasefire w/ Hezbollah
Judge tosses election case
World's oldest man dies
To attend inauguration
Thanksgiving storm forecast
Best-selling author dies
LA homeless sweeps halted
Defamation suit to proceed
Request to bar player denied
25 years for killing neighbor
Rolling back DEI policies
Wins approval for $6.6B loan
Local dengue case in Texas
Safety issue grounds Osprey
FBI agent charged w/ assault
Alleged impropriety probe
Donates more than $1B
Excluded from EV tax plan
Treasury yields drop
MA synagogues threat plea
Federal prosecutor to resign
Leech charged with fraud
MO trans care ban upheld
Settles suit over pay equity
DNC sets election for chair
Google's US antitrust trial
Faces April trial in FTC case
Rays stadium deal deadline
Feedback